JP2025514142A5 - - Google Patents
Info
- Publication number
- JP2025514142A5 JP2025514142A5 JP2024563061A JP2024563061A JP2025514142A5 JP 2025514142 A5 JP2025514142 A5 JP 2025514142A5 JP 2024563061 A JP2024563061 A JP 2024563061A JP 2024563061 A JP2024563061 A JP 2024563061A JP 2025514142 A5 JP2025514142 A5 JP 2025514142A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- amino acid
- acid sequence
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263334381P | 2022-04-25 | 2022-04-25 | |
| US63/334,381 | 2022-04-25 | ||
| US202263374646P | 2022-09-06 | 2022-09-06 | |
| US63/374,646 | 2022-09-06 | ||
| PCT/US2023/066114 WO2023212518A1 (en) | 2022-04-25 | 2023-04-24 | Antibody molecules to april and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514142A JP2025514142A (ja) | 2025-05-02 |
| JP2025514142A5 true JP2025514142A5 (enExample) | 2026-05-01 |
Family
ID=86332309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563061A Pending JP2025514142A (ja) | 2022-04-25 | 2023-04-24 | Ａｐｒｉｌに対する抗体分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240092921A1 (enExample) |
| EP (1) | EP4514381A1 (enExample) |
| JP (1) | JP2025514142A (enExample) |
| KR (1) | KR20250018167A (enExample) |
| CN (1) | CN119730874A (enExample) |
| AU (1) | AU2023262513A1 (enExample) |
| CA (1) | CA3256431A1 (enExample) |
| TW (1) | TW202400637A (enExample) |
| WO (1) | WO2023212518A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170145086A1 (en) | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| AU2023366516A1 (en) * | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2026050274A2 (en) * | 2024-08-27 | 2026-03-05 | Paragon Therapeutics, Inc. | April binding proteins, compositions, and methods of use thereof |
| WO2026122561A2 (en) * | 2024-12-03 | 2026-06-11 | Otsuka America Pharmaceutical, Inc. | Methods of treating sjögren's disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US20210340266A1 (en) * | 2008-10-09 | 2021-11-04 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2010100056A2 (en) | 2009-03-02 | 2010-09-10 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170145086A1 (en) * | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| AU2021279035A1 (en) | 2020-05-29 | 2023-02-02 | Aduro Biotech Holding, Europe B.V. | Methods of treating IgA nephropathy with an APRIL binding antibody |
| KR20230042273A (ko) * | 2020-06-24 | 2023-03-28 | 비스테라, 인크. | April에 대한 항체 분자 및 그의 용도 |
-
2023
- 2023-04-24 AU AU2023262513A patent/AU2023262513A1/en active Pending
- 2023-04-24 KR KR1020247038918A patent/KR20250018167A/ko active Pending
- 2023-04-24 CA CA3256431A patent/CA3256431A1/en active Pending
- 2023-04-24 EP EP23723396.0A patent/EP4514381A1/en active Pending
- 2023-04-24 TW TW112115157A patent/TW202400637A/zh unknown
- 2023-04-24 JP JP2024563061A patent/JP2025514142A/ja active Pending
- 2023-04-24 CN CN202380048107.0A patent/CN119730874A/zh active Pending
- 2023-04-24 WO PCT/US2023/066114 patent/WO2023212518A1/en not_active Ceased
- 2023-04-24 US US18/305,667 patent/US20240092921A1/en active Pending
-
2024
- 2024-08-23 US US18/814,058 patent/US20250043014A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3487883B1 (en) | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 | |
| JP2023548858A5 (enExample) | ||
| Rezaei et al. | Indications and safety of intravenous and subcutaneous immunoglobulin therapy | |
| TWI701041B (zh) | 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法 | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2013166765A5 (enExample) | ||
| RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
| KR102101478B1 (ko) | 자가면역 및 염증성 질환의 치료를 위한 방법 및 조성물 | |
| JP2024127990A (ja) | アミロイドーシスを処置するための組成物 | |
| Suri et al. | Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab | |
| Linker et al. | Use of intravenous immunoglobulin and plasma exchange in neurological disease | |
| Sudo et al. | Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies | |
| JP2023531722A5 (enExample) | ||
| CN105017414A (zh) | 偶联重组Pro-A和/或G多糖亲和介质及其应用 | |
| Elliott et al. | Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases | |
| Lotan et al. | Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease | |
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| JP2024539751A (ja) | 抗ｃｄ２２抗体の水性製剤およびそれらの使用 | |
| CN116440263A (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| Bujnowska et al. | Outcomes of prolonged treatment with intravenous immunoglobulin infusions for acute antibody-mediated rejection in kidney transplant recipients | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| WO2023025249A1 (zh) | 一种含融合蛋白的药物组合物 | |
| Harding | Eculizumab | |
| CN114901313A (zh) | 急性期的视神经脊髓炎的预防或治疗剂 | |
| RU2024134791A (ru) | Молекулы анти-april антитела и их применение |